- Emyria (EMD) has received Therapeutic Goods Administration (TGA) approval for its Openly app, which will used in several upcoming clinical trials
- The app utilises the capabilities of a smartphone to provide medical-grade measurements of an individual’s heart rate
- Software-based medical devices, like Apple’s HealthKit, are gaining increasing traction as verified healthcare products
- It can now used to remotely monitor patients in clinical studies, also provide telehealth services to patients and enable other consumer healthcare products
- The Openly app can also used to facilitate the development of other medical technologies
- Emyria is up 0.91 per cent to $0.22 per share
